Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More
Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PROCTER & GAMBLE HEALTH Dec-18 |
TEVA PHARMA Dec-13 |
PROCTER & GAMBLE HEALTH/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 3,549 | 3,043 | - | |
Low | Rs | 1,301 | 2,643 | - | |
Sales per share (Unadj.) | Rs | 511.4 | 1,746.3 | - | |
Earnings per share (Unadj.) | Rs | 61.3 | 109.1 | - | |
Cash flow per share (Unadj.) | Rs | 74.0 | 250.2 | - | |
Dividends per share (Unadj.) | Rs | 440.00 | 95.50 | - | |
Dividend yield (eoy) | % | 18.1 | 3.4 | 540.1% | |
Book value per share (Unadj.) | Rs | 927.8 | 1,939.8 | - | |
Shares outstanding (eoy) | m | 16.60 | 848.00 | - | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 4.7 | 1.6 | 291.3% | |
Avg P/E ratio | x | 39.6 | 26.1 | 151.8% | |
P/CF ratio (eoy) | x | 32.8 | 11.4 | 288.4% | |
Price / Book Value ratio | x | 2.6 | 1.5 | 178.3% | |
Dividend payout | % | 717.9 | 87.5 | 820.1% | |
Avg Mkt Cap | Rs m | 40,257 | 2,410,949 | 1.7% | |
No. of employees | `000 | 1.1 | 44.9 | 2.5% | |
Total wages/salary | Rs m | 1,313 | 0 | - | |
Avg. sales/employee | Rs Th | 7,486.7 | 32,949.0 | 22.7% | |
Avg. wages/employee | Rs Th | 1,157.6 | 0 | - | |
Avg. net profit/employee | Rs Th | 897.2 | 2,058.3 | 43.6% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 8,490 | 1,480,891 | 0.6% | |
Other income | Rs m | 244 | 0 | - | |
Total revenues | Rs m | 8,734 | 1,480,891 | 0.6% | |
Gross profit | Rs m | 1,482 | 405,543 | 0.4% | |
Depreciation | Rs m | 211 | 119,702 | 0.2% | |
Interest | Rs m | 0 | 29,087 | 0.0% | |
Profit before tax | Rs m | 1,514 | 256,754 | 0.6% | |
Minority Interest | Rs m | 0 | 1,166 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 66 | -168,545 | -0.0% | |
Tax | Rs m | 563 | -3,135 | -17.9% | |
Profit after tax | Rs m | 1,017 | 92,510 | 1.1% | |
Gross profit margin | % | 17.5 | 27.4 | 63.7% | |
Effective tax rate | % | 37.1 | -1.2 | -3,042.5% | |
Net profit margin | % | 12.0 | 6.2 | 191.8% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 15,343 | 1,000,188 | 1.5% | |
Current liabilities | Rs m | 1,960 | 872,249 | 0.2% | |
Net working cap to sales | % | 157.6 | 8.6 | 1,824.6% | |
Current ratio | x | 7.8 | 1.1 | 682.6% | |
Inventory Days | Days | 49 | 91 | 53.7% | |
Debtors Days | Days | 28 | 96 | 29.7% | |
Net fixed assets | Rs m | 1,209 | 483,692 | 0.3% | |
Share capital | Rs m | 166 | 3,645 | 4.6% | |
Net worth | Rs m | 15,401 | 1,644,989 | 0.9% | |
Long term debt | Rs m | 0 | 757,212 | 0.0% | |
Total assets | Rs m | 17,595 | 3,384,310 | 0.5% | |
Interest coverage | x | NM | 9.8 | - | |
Debt to equity ratio | x | 0 | 0.5 | 0.0% | |
Sales to assets ratio | x | 0.5 | 0.4 | 110.3% | |
Return on assets | % | 5.8 | 3.6 | 160.9% | |
Return on equity | % | 6.6 | 5.6 | 117.5% | |
Return on capital | % | 10.3 | 4.9 | 208.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | -1,304 | 235,977 | -0.6% | |
From Investments | Rs m | 12,697 | -83,616 | -15.2% | |
From Financial Activity | Rs m | -301 | -283,071 | 0.1% | |
Net Cashflow | Rs m | 11,093 | -130,710 | -8.5% |
Compare PROCTER & GAMBLE HEALTH With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US)
Compare PROCTER & GAMBLE HEALTH With: J.B.CHEMICALS DR. REDDYS LAB PIRAMAL ENTERPRISES SUVEN LIFE SCIENCES DR. DATSONS LABS
Indian share markets witnessed huge selling during closing hours today and ended their day lower.
For the quarter ended June 2020, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 692 m (up 57.0% YoY). Sales on the other hand came in at Rs 6 bn (up 171.6% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.
For the quarter ended September 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 358 m (down 13.0% YoY). Sales on the other hand came in at Rs 2 bn (down 0.4% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.
Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll show you how to get started on the path to daily trading profits.
An Indian company founded three decades ago in a garage caught my attention...
In this video, I'll show you how to allocate your capital as a day trader.
More